Angelman syndrome

Overview

Angelman syndrome is a neurodevelopmental condition that typically becomes apparent during infancy, when parents notice delayed milestones and distinctive movement patterns. Children with this condition experience profound intellectual disability and generally do not develop functional speech, though they can communicate through gestures, sign language, or communication devices. The condition takes its name from Dr Harry Angelman, a British paediatrician who first described the disorder in 1965 after observing three children with similar features including jerky movements, frequent laughter, and severe learning difficulties.

The condition results from absent or non-functional UBE3A protein specifically in the brain. This protein plays a critical role in normal neurological development, and its loss leads to the characteristic features of the syndrome. Angelman syndrome presents significant challenges, yet many affected individuals lead fulfilling lives with appropriate support, therapy, and educational interventions tailored to their abilities.

Angelman syndrome occurs across all ethnic groups and affects males and females equally. The condition is present from birth, though the full clinical picture may not be recognised until the second year of life when developmental delays become more apparent. Early identification through genetic testing allows families to connect with specialist services and plan appropriate interventions.

Symptoms & clinical features

The clinical features of Angelman syndrome typically emerge gradually during the first years of life. Developmental delay is usually the first concern, with affected infants showing delayed sitting, crawling, and walking. When children do begin walking, typically between ages two and six years, they display a characteristic stiff-legged, wide-based gait with jerky movements. This ataxic pattern of movement, combined with tremulous limb motions, creates a distinctive appearance that clinicians recognise as suggestive of the condition.

Speech development is profoundly affected in Angelman syndrome. Most individuals never develop functional verbal language, though they understand simple instructions and can communicate their needs through non-verbal means. Despite the severe speech impairment, affected individuals typically display a remarkably happy disposition with frequent smiling and laughter, often appearing easily excitable. This behavioural phenotype can sometimes mask the severity of the underlying disability. Sleep disturbances affect the majority of individuals, with difficulty falling asleep and frequent night-time waking creating significant challenges for families.

Seizures are common in Angelman syndrome, usually beginning before age three years. The seizure types vary but commonly include atypical absence seizures and myoclonic jerks. Additional features may include microcephaly (smaller than expected head size), a wide mouth with widely spaced teeth, a prominent jaw, and fair hair and pale skin compared to other family members. Reduced pigmentation occurs particularly in individuals whose condition results from a deletion of the chromosomal region, as nearby pigmentation genes are also lost. Many affected individuals develop scoliosis during childhood or adolescence, requiring monitoring and sometimes orthopaedic intervention.

Video: Genetics 101

Affected organs

Angelman syndrome primarily affects the central nervous system, with the brain showing the most significant impact. Neuroimaging studies may reveal mild cerebral atrophy and enlarged ventricles in some individuals, though brain structure can appear normal in others. The cerebellum, which coordinates movement and balance, functions abnormally, accounting for the ataxic gait and tremulous movements. Electroencephalography typically shows characteristic abnormal brain wave patterns, even in individuals who have not experienced clinical seizures, reflecting widespread disruption of normal neurological activity.

The musculoskeletal system is secondarily affected through the neurological impairment. Low muscle tone in infancy often progresses to increased muscle tone in later childhood. The spine frequently develops curvature, with scoliosis affecting a substantial proportion of individuals and sometimes progressing to require surgical correction. The gastrointestinal system may be involved, with feeding difficulties common in infancy and constipation frequently persisting throughout life. Some individuals experience gastro-oesophageal reflux. The sleep-wake cycle is disrupted due to abnormal regulation of circadian rhythms in the brain, leading to the characteristic sleep disturbances that affect quality of life for both the affected person and their family.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

Angelman syndrome represents a lifelong condition with significant impact on daily functioning. All affected individuals experience severe to profound intellectual disability, and the vast majority never develop speech beyond a few words. Independence in activities of daily living remains limited, with most people requiring substantial support throughout their lives. However, the severity of individual features shows some variation. Seizures, when present, often improve during adolescence, though they may persist into adulthood in some individuals. The movement difficulties typically remain stable rather than progressive.

Life expectancy appears not to be dramatically reduced for most individuals with appropriate medical care and support, though specific longevity data are not well established. Certain complications require monitoring. Seizures occasionally prove difficult to control despite medication, and there exists a small risk of sudden unexpected death in epilepsy. Severe scoliosis can compromise respiratory function if untreated. Obesity may develop in adolescence and adulthood, potentially leading to associated health complications. Aspiration due to swallowing difficulties poses a risk in some individuals.

The happy demeanour characteristic of Angelman syndrome can create challenges in recognising pain, illness, or distress. Caregivers learn to interpret subtle changes in behaviour as potential indicators of medical issues. Sleep disturbances, whilst not life-threatening, significantly impact family quality of life and may require specific management strategies. Despite the substantial challenges, many individuals with Angelman syndrome form strong bonds with family members, respond positively to music and water-based activities, and demonstrate genuine enjoyment of life within their capabilities.

Genetic causes

Angelman syndrome results from loss of function of UBE3A, which encodes a protein called ubiquitin protein ligase E3A. Within cells, this protein participates in marking other proteins for degradation when they become damaged or surplus to requirements. In nerve cells, UBE3A contributes to maintaining appropriate protein concentrations that support normal synaptic activity and the brain's capacity to modify connections based on learning and experience.

The molecular basis of Angelman syndrome involves an unusual feature called genomic imprinting. For most human genes, both the maternally inherited and paternally inherited copies are active. However, UBE3A demonstrates parent-specific expression in particular brain regions. Within neurons, only the copy inherited from the mother produces protein, whilst the father's copy remains inactive through chemical modification. Consequently, normal brain development depends entirely on receiving a working maternal UBE3A copy. Should the maternal version be missing, damaged, or otherwise unable to function, no UBE3A protein appears in neurons, irrespective of the paternal copy's status.

Several distinct molecular mechanisms can cause Angelman syndrome. A portion of individuals lack a segment of the maternal chromosome 15 in the region designated 15q11-q13, which eliminates UBE3A alongside adjacent genes. Others carry a mutation specifically disrupting the maternal UBE3A sequence itself. Some affected individuals inherit both chromosome 15 copies from their father and neither from their mother, a situation termed paternal uniparental disomy that leaves them without any functional maternal UBE3A. Occasionally, defects occur in the regulatory elements controlling whether genes in this chromosomal region switch on or remain silent. In some individuals displaying clinical signs of Angelman syndrome, current laboratory methods cannot identify the underlying genetic alteration, though these cases are presumed to involve disruption of UBE3A activity through mechanisms not yet fully characterised.

• UBE3A
  ubiquitin protein ligase E3A

Inheritance pattern

Angelman syndrome typically arises as a new genetic change rather than being inherited from a parent. In the most common scenario, where the condition results from a deletion of maternal chromosome 15q11-q13 or a new mutation in maternal UBE3A, the genetic change occurs spontaneously during formation of the egg cell or in early embryonic development. Parents of an affected child usually have normal chromosomes, and the recurrence risk for future pregnancies is low, generally quoted as less than 1%.

However, in rare circumstances, Angelman syndrome can follow an autosomal dominant inheritance pattern. If a mother carries a UBE3A mutation, she has a 50% chance of passing that mutated gene to each child. Because only the maternal copy of UBE3A is active in the brain, any child who inherits the mutated maternal copy will develop Angelman syndrome. Interestingly, if a father carries a UBE3A mutation and passes it to his children, they will not develop Angelman syndrome because the paternal copy is normally silenced in brain cells anyway. This parent-of-origin effect creates an unusual inheritance pattern where the same mutation causes disease only when inherited from the mother.

When Angelman syndrome results from an imprinting centre defect, the inheritance pattern depends on whether the imprinting defect itself is due to a deletion. Imprinting centre deletions can be inherited and carry a 50% recurrence risk, whilst imprinting defects without a deletion (imprinting mutations) typically occur sporadically. Genetic counselling is essential for families affected by Angelman syndrome, as the recurrence risk varies substantially depending on the underlying molecular mechanism. Testing of parents may be recommended to clarify whether a heritable genetic change is present, which informs reproductive planning and enables consideration of options such as prenatal diagnosis or preimplantation genetic testing for future pregnancies.

Diagnosis & testing

Diagnosis of Angelman syndrome begins with clinical recognition of the characteristic features, typically prompting referral to paediatric neurology or clinical genetics services. The combination of severe developmental delay, absent speech, ataxic movements, happy demeanour, and seizures raises strong clinical suspicion. However, definitive diagnosis requires genetic testing to identify the underlying molecular abnormality. Within the NHS, Angelman syndrome is included in relevant testing pathways for neurodevelopmental disorders, and testing is typically arranged through specialist paediatric or genetics services.

The genetic testing approach for Angelman syndrome is stepwise, as different molecular mechanisms require different techniques. DNA methylation analysis of the 15q11-q13 region serves as the initial screening test, as it can detect the majority of cases (those due to deletion, uniparental disomy, or imprinting defects). If methylation testing is abnormal, further analysis determines the specific mechanism. If methylation analysis is normal but clinical suspicion remains high, sequencing of UBE3A identifies pathogenic variants in the maternal copy. Chromosomal microarray may be performed to detect deletions and determine their size. In families where a specific genetic cause has been identified, targeted testing for that particular change enables rapid diagnosis in subsequently affected family members and allows prenatal or preimplantation genetic testing if desired.

Management & lifestyle

Management of Angelman syndrome centres on supportive care tailored to individual needs, with input from multiple specialties coordinated through community paediatric or neurodevelopmental services. Early intervention programmes, including physiotherapy to address motor delays and low muscle tone, can optimise developmental progress. Occupational therapy helps with daily living skills and may include provision of adaptive equipment. Speech and language therapy focuses on developing non-verbal communication methods, and many individuals benefit from learning sign language or using communication devices with pictures or symbols.

Seizure management requires input from paediatric neurology, with treatment individualised based on seizure type and frequency. Several antiepileptic medications have shown effectiveness in Angelman syndrome, though seizures can prove challenging to control in some individuals. Sleep disturbances often respond to behavioural interventions establishing consistent bedtime routines, though some individuals require melatonin supplementation to regulate their sleep-wake cycle. Behavioural support addresses challenges such as short attention span, hyperactivity, and mouthing behaviours, using positive behaviour strategies and environmental modifications.

Orthopaedic monitoring for scoliosis is essential, as early detection allows conservative management with bracing in some cases, potentially preventing progression that would require surgical intervention. Constipation typically responds to dietary modifications, adequate fluid intake, and laxatives when needed. Educational provision through special educational needs services focuses on functional skills and maximising independence within each individual's capabilities. Physical activity is encouraged, with many individuals particularly enjoying swimming and music-based therapies. Families benefit from connecting with support organisations and other families affected by Angelman syndrome, sharing practical strategies and accessing information about emerging research.

UK care pathway

Within the NHS Genomic Medicine Service, Angelman syndrome is included in testing pathways for developmental disorders and early-onset epilepsy. When clinical features suggest the diagnosis, referral to clinical genetics or paediatric neurology initiates the diagnostic pathway. Genetic testing is arranged through these specialist services, with results interpreted in the context of the clinical presentation. The relevant R-code classifications help ensure appropriate test selection, with Angelman syndrome falling under neurodevelopmental disorder panels on PanelApp.

Once a genetic diagnosis is confirmed, genetic counsellors provide detailed information about the condition, explain the specific genetic mechanism identified, and discuss recurrence risks for the family. They facilitate access to support organisations and can arrange predictive or prenatal testing for relatives if appropriate. Ongoing care is typically coordinated through community paediatrics, with input from neurology, orthopaedics, and therapy services as needed. Transition to adult services during adolescence requires careful planning to ensure continuity of care, as individuals with Angelman syndrome require lifelong support. The 100,000 Genomes Project and ongoing research through NHS genetics services contribute to improving understanding of the molecular mechanisms and genotype-phenotype correlations in Angelman syndrome.

Related conditions

Several other genetic conditions share clinical features with Angelman syndrome and may be considered in the differential diagnosis. Prader-Willi syndrome, interestingly, results from abnormalities of the same chromosomal region (15q11-q13) but affecting the paternally expressed genes rather than maternal UBE3A. Whilst Prader-Willi syndrome also causes developmental delay and behavioural differences, the clinical picture differs substantially, with hypotonia and feeding difficulties in infancy progressing to hyperphagia and obesity in childhood, contrasting with the movement disorder and happy affect of Angelman syndrome.

Rett syndrome, caused by pathogenic variants in MECP2, shares some features with Angelman syndrome including developmental regression, absent speech, and hand stereotypies, but typically affects only females and includes a period of normal early development followed by regression, which is not characteristic of Angelman syndrome. Other Rett-like disorders and conditions causing ataxia, developmental delay, and seizures may require genetic testing to distinguish from Angelman syndrome. Christianson syndrome, due to SLC9A6 pathogenic variants, can present with similar features including intellectual disability, absent speech, ataxia, and seizures. Comprehensive genetic testing, including chromosomal microarray and gene panel or exome sequencing, helps differentiate between these conditions when clinical features overlap, ensuring accurate diagnosis and appropriate management.

Frequently asked questions

References

1. Yang L, Shu X, Mao S. Genotype-Phenotype Correlations in Angelman Syndrome. Genes. 2021. PMID: 34203304
2. Maranga C, Fernandes TG, Bekman E. Angelman syndrome: a journey through the brain. The FEBS journal. 2020. PMID: 32087041
3. Manssen L, Krey I, Gburek-Augustat J. Precision Medicine in Angelman Syndrome. Neuropediatrics. 2025. PMID: 39168152
4. Keary CJ, McDougle CJ. Current and emerging treatment options for Angelman syndrome. Expert review of neurotherapeutics. 2023. PMID: 37599585
5. Williams CA, Zori RT, Hendrickson J. Angelman syndrome. Current problems in pediatrics. 1995. PMID: 8521718
6. Hunter G. Baby Jack. JAMA. 2025. PMID: 39847371
7. Grebe SC, Limon DL, McNeel MM. Anxiety in Angelman Syndrome. American journal on intellectual and developmental disabilities. 2022. PMID: 34979033
8. Clayton-Smith J. Angelman's syndrome. Archives of disease in childhood. 1992. PMID: 1519953